CCXI Summary

  1. NASDAQ
  2. >
  3. CCXI
TickerCCXI
DescriptionCHEMOCENTRYX INC
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
ExchangeNASDAQ
TypeStock
SectorHealthcare
Employees133
Next Earnings DateNovember 8th, 2021
IV308.306759%
IV Percentile99th
IV Rank100.00%
IV Skew15.835503
IV Skew Percentile99th
IV Skew SentimentBearish
Option Volume14,291
Volume2,137,634
Price$18.10
Previous Close$17.97
52-Week High$70.29
52-Week Low$9.53
50-Day Moving Avg.$15.39
200-Day Moving Avg.$24.33
10-Day Avg. Volume1,382,040
20-Day Avg. Volume1,218,274
30-Day Avg. Volume1,217,219
3-Month Avg. Volume2,091,815
EPS-$1.81
Outstanding Shares69,903,505
Market Capitalization$1,201,641,300
CurrencyUSD
UpdatedSeptember 24th, 2021